Diabetes
Refine Search
Biotechnology
MannKind has resubmitted its New Drug Application to the FDA for the marketing and sale of Afrezza Inhalation Powder for adults with type 1 or type 2 diabetes. 14 October 2013
Pharmaceutical
New data published on-line in Diabetes Care, today Care demonstrating positive effects of USA-based Vivus’ obesity drug Qsymia (phentermine and topiramate extended-release) on the progression to type 2 diabetes. 10 October 2013
Pharmaceutical
Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a recent analysis undertaken by the health care unit at Frost & Sullivan Africa. 8 October 2013
Biotechnology
Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term sheet for the clinical development of EV-077, Evolva’s compound targeted at diabetic nephropathy (progressive kidney disease caused by diabetes). 7 October 2013
Pharmaceutical
Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia (lixisenatide), when added to basal insulin, were greatest in patients with type 2 diabetes who had well-controlled baseline fasting plasma glucose. 5 October 2013
Pharmaceutical
Through analysis of US longitudinal patient-level claims data, dipeptidyl peptidase (DPP-IV) inhibitors claim the largest share among branded oral therapies of newly diagnosed type 2 diabetes patients across all three lines of therapy. 3 October 2013
Pharmaceutical
Bristol-Myers Squibb and partner AstraZeneca have announced additional results from the SAVOR cardiovascular outcomes trial. 27 September 2013
Pharmaceutical
French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial site in Algeria. 26 September 2013
Pharmaceutical
Geropharm, one of Russia’s leading pharmaceutical and biotech companies, is establishing a plant for the production of insulin in the city of Obolensk, in the Moscow region. 25 September 2013
Pharmaceutical
The global type 2 diabetes market is expected to grow from $20.4 billion in 2012 to $38.8 billion by 2019, at a compound annual growth rate of 10.2%, forecasts business intelligence provider GBI Research. 25 September 2013
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceutical has received marketing authorization from the European Commission for Vipidia for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies. 24 September 2013
Pharmaceutical
UK contract development and manufacturing organization (CDMO) Aesica Pharmaceuticals has announced the creation of a new High Capacity Manufacturing Facility following a £30 million ($47.6 million) investment. 19 September 2013
Biotechnology
French drug major Sanofi's (Euronext: SAN) decision to withdraw Lyxumia's (lixisenatide)... 18 September 2013
Biotechnology
A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular pathway - a series of interaction among proteins - involved in the development of diabetes. Furthermore, they have found that a drug already approved for use in humans can regulate the pathway. The findings were published on-line September 15 in two articles in Nature Medicine and reported by EurekAlert. 16 September 2013
Pharmaceutical
Last week in the Ukraine, the Association of Pharmaceutical Research and Development (APRaD) and the American Chamber of Commerce (ACC) in Ukraine issued a join position paper regarding the problems with reforming the provision of diabetes mellitus patients with the necessary medicines. 16 September 2013
Pharmaceutical
Japanese drugmakers Kissei Pharmaceutical (TYO: 4547) and Takeda Pharmaceutical (TYO: 4502) have received approval of an application for partial changes of indication of Glufast (mitiglinide) by the Ministry of Health, Labor and Welfare (MHLW) in Japan. 13 September 2013
Pharmaceutical
French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw the diabetes drug candidate lixisenatide New Drug Application in the USA, which included early interim results from the ongoing ELIXA cardiovascular (CV) outcomes study. 12 September 2013
Biotechnology
US drug developer ChemoCentryx (Nasdaq: CCXI) announced interim data from an ongoing Phase II study in patients with diabetic nephropathy, also known as diabetic kidney disease, with CCX140, an inhibitor of the chemokine receptor known as CCR2, which is wholly owned by the company. 12 September 2013
Pharmaceutical
USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license agreement with a subsidiary of pharma giant Merck & CO (NYSE: MRK) for certain patents directed to metformin extended release technology for use in XR (sitagliptin and metformin hydrochloride extended-release). The territory covered by the license agreement is now worldwide. 10 September 2013
Pharmaceutical
Drug regulator the Scottish Medicines Consortium (SMC) has today approved the National Health Service use of Swiss pharma major Roche's (ROG: SIX) MabThera (rituximab) for patients suffering from potentially fatal forms of vasculitis. 10 September 2013
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze